Vasoactive intestinal peptide (VIP) is present in the peripheral and the central nervous systems where it functions as a nonadrenergic, noncholinergic neurotransmitter or neuromodulator. Significant concentrations of VIP are present in the gastrointestinal tract, heart, lungs, thyroid, kidney, urinary bladder, genital organs and the brain. On a molar basis, VIP is 50-100 times more potent than acetylcholine as a vasodilator. VIP release in the body is stimulated by high frequency (10-20 Hz) nerve stimulation and by cholinergic agonists, serotonin, dopaminergic agonists, prostaglandins (PGE, PGD), and nerve growth factor. The VIP peptide combines with its receptor and dose-dependently activates adenylyl cyclase. The vasodilatory effect of VIP in different vascular tissues or species also may be due to increases in nitric oxide, cyclic GMP, and other signaling agents. In the heart, VIP immunoreactive nerve fibers are present not only in the epicardial coronary arteries and veins, but also the sinoatrial node, atrium, interatrial septum, atrioventricular node, intracardiac ganglia, and ventricles (right ventricle4left ventricle). In the coronary arterial walls, VIP may contribute to the regulation of normal coronary vasomotor tone. In research animals and in humans, VIP, administered into the coronary artery or intravenously, increases the epicardial coronary artery cross-sectional area, decreases coronary vascular resistance, and significantly increases coronary artery blood flow. High frequency parasympathetic (vagal) nerve stimulation also releases endogenous VIP in the coronary vessels and heart and significantly increases coronary artery blood flow. In addition, the release of VIP in the heart is increased during coronary artery occlusion and during reperfusion where VIP may promote local blood flow and may have a free-radical scavenging effect. VIP also has a primary positive inotropic effect on cardiac muscle that is enhanced by its ability to facilitate ventricular-vascular coupling by reducing mean arterial 28 25
a PACAP27 has 70% homology with VIP, PHI has 48% homology, secretin has 33% homology and glucagon has 20% homology with VIP. The VIP sequence is identical in human, rat, rabbit, dog, sheep, goat and cow but differs in four amino acid substitutions in the guinea pig (gp). The one-letter codes for the amino acids are: Ala, A; Cys, C; His, H; Met, M; Thr, T; Arg, R; Glu, E; Ile, I; Phe, F; Trp, W; Asn, N; Gln, Q; Leu, L; Pro, P; Tyr, Y; Asp, D; Gly, G; Lys, K; Ser, S; Val, V. rabbit and rat is identical to that of the porcine peptide [6] .
sciatic nerve, autonomic nerves that supply exocrine Guinea pig VIP and non-mammalian VIP (chicken, alglands, vascular and nonvascular smooth muscle, and ligator, frog, trout, bowfin, dogfish, cod, and goldfish) ganglion-like clusters of neuronal cell bodies that provide differ from the human sequence at only four or five 'intrinsic' organ innervation [11, 12] . The gastrointestinal positions [6] . The VIP gene has been cloned, sequenced, tract, heart, lungs, thyroid, kidney, urinary bladder, and and localized to chromosome 6q24 [7] [8] [9] .
genital organs contain significant concentrations of VIP. In The VIP peptide is derived from prepro-VIP, which the central nervous system, VIP is present in the cerebral consists of 170 amino acid residues [6] . Proteolytic cortex, the hypothalamus, amygdala, hippocampus, corpus cleavage of prepro VIP yields: prepro VIP(22-79), peptide striatum, and the vagal centers of the medulla oblongata histidine isoleucine / methionine (PHI / PHM) , [6, 13, 14] . prepro VIP (111) (112) (113) (114) (115) (116) (117) (118) (119) (120) (121) (122) , VIP , and prepro VIP(156-In the peripheral nervous system, VIP containing neu-170) [6] (Fig. 1) . Peptide histidine isoleucine / methionine rons are either intrinsic neurons involved in local reflexes, is structurally related to VIP and shares many of VIP's or postganglionic neurons under preganglionic cholinergic biological actions but is generally less potent than VIP.
(nicotinic) control [15] . In postganglionic neurons, VIP is Other peptide sequences have been identified during the synthesized in neuronal cell bodies and is then exported proteolytic cleavage of the VIP precursor but have limited along axons or dendrites to large 100 nm spherical dense biological effects. Nevertheless, the bioactivity of these core vesicles located in presynaptic nerve terminals partial sequences of VIP increases with increasing amino [16, 17] . The transport rate of VIP to nerve terminals is acid chain length [10] .
approximately 9 mm / h [17] . Many systemic blood vessels Early investigators hypothesized that VIP occurred in and also pulmonary blood vessels are innervated by VIP 'endocrine-like' cells in the gastrointestinal tract. Subimmunoreactive nerve fibers, which cause vascular smooth sequently VIP was discovered in nerve cell bodies and muscle dilation [15] . In this regard, VIP, on a molar basis, axons in the gastrointestinal wall and in the peripheral and is 50 to 100 times more potent than acetylcholine as a central nervous systems where the peptide functions as a vasodilator [11] . In addition, VIP facilitates the secretory nonadrenergic, noncholinergic neuropeptide transmitter or response to acetylcholine in glandular epithelium and is neuromodulator. Immunofluorescent and radioimmunoasinvolved in the control of exocrine as well as endocrine say studies have localized VIP to neuronal cell bodies, secretion, not only in the gastrointestinal tract but also in axons and dendrites, and presynaptic nerve terminals from the respiratory and urogenital tracts [15, 18, 19] . Endogenwhich VIP is released as a neurotransmitter [11] . In the ous VIP is released by high frequency nerve stimulation peripheral nervous system, VIP is present in sympathetic [17] and also is released by neostigmine, as well as by ganglia, the vagus nerves, some motor nerves such as the serotonin, dopaminergic agonists such as bromocriptine and apomorphine, prostaglandins (PGE, PGD) and nerve vessels [32, 33] , aorta [34] [35] [36] , heart and coronary vessels growth factor [20] . [37] [38] [39] [40] , the mesenteric artery [41, 42] , portal vein [43] and In the central nervous system, VIP contributes to the ovarian artery [44] ( Table 2 ). The degree of VIP-induced regulation of cerebral blood flow, energy metabolism and activation of adenylyl cyclase varies with the species (rat, enzymatic activity, and is twenty times more potent than rabbit, dog, cat, monkey) and also the organ or tissue norepinephrine in stimulating the enzymatic breakdown of [45, 46] . In the rat, VIP increases adenylyl cyclase activity glycogen to glucose [6, 13, 14] . VIP is also involved in the in a dose and GTP-dependent fashion with an EC value 50 28 26 release of corticotropin-releasing hormone, prolactin, oxythat varies with the tissue from 10 to 10 M [32,37,41] tocin, and vasopressin [21] .
( Table 2 ). The dose-dependent increase in adenylyl cyclase activity and cAMP concentration corresponds well with 1.2. VIP receptors VIP's ability to produce vasodilation in isolated arteries [41] . In cerebral microvessels, the effects of VIP on The VIP receptor is a member of a family of guanine adenylyl cyclase activity are additive with the effects of nucleotide binding protein (G protein)-coupled receptors isoproterenol, 2-chloroadenosine, and prostaglandin E1 which include receptors for pituitary adenylate cyclase [32] . This suggests compartmentalization of the effects of activating polypeptide (PACAP), secretin, glucagon, cal-VIP on adenylyl cyclase activity, possibly involving citonin, parathyroid hormone, growth hormone-releasing different receptors, G proteins, and adenylyl cyclase factor (GHRF) and corticotropin-releasing factor [22, 23] .
isozymes. In the rat mesenteric artery, VIP is 100-fold VIP receptors are present in the heart [24] and blood more potent than isoproterenol and prostaglandin E1 in vessels [25, 26] , as well as in many other tissues, and have enhancing adenylyl cyclase activity [41] . Moreover, seca molecular weight of 43 000-80 000 daltons. This variretin, gastric inhibitory peptide, glucagon, angiotensin-II, ability in molecular weight is consistent with either cellor substance P do not alter VIP's activation of adenylyl specific differential glycosylation of the same receptor or cyclase in the portal vein [43] . receptor heterogeneity. Two subtypes of VIP receptors,
In vascular smooth muscle, a VIP-induced increase in VPAC1 and VPAC2, have been cloned from rat and human cAMP concentration can activate protein kinase A, which tissue and sequenced, and there is 50% identity between phosphorylates phospholamban, and thereby increases the 21 the two receptor subtypes [27] [28] [29] . These receptors are sequestration of Ca by the sarcoplasmic reticulum [47] . identical to the PACAP type 2 and 3 receptors. The two Cyclic AMP can also increase the activity of the sarcolem- 21 subtypes of the VIP receptor share characteristics also seen mal Ca pump ATPase, thereby increasing the extrusion 21 in other members of the secretin receptor family, including of Ca into the extracellular space. In addition, cAMP an extensive amino-terminal signal peptide recognition decreases the affinity of myosin light chain kinase for the 21 sequence, several extracellular glycosylation sites and Ca -calmodulin complex, thereby reducing myosin phoscysteine residues, seven transmembrane-spanning domains phorylation and decreasing actin-myosin affinity [47] . and a number of intracellular sites for phosphorylation by These processes when activated by VIP can produce protein kinase C [27] [28] [29] . VPAC1 receptors are widely smooth muscle relaxation and vasodilation. distributed in the central nervous system (cerebral cortex,
The vasodilatory effect of VIP in different vascular amygdaloid nuclei, hippocampus), and in the liver, lung, tissues or species is not solely due to an increase in cyclic intestine and are also present in aorta, heart, adipose tissue, AMP. The vasorelaxant effect of VIP is dependent on the and blood vessels of the pancreas, intestine, and heart endothelium in the rat aorta, the bovine intrapulmonary [6, 14, 27, 29, 30] . VPAC2 receptors are abundant in the artery, and the human uterine artery, and is mediated by olfactory lobes, thalamus, and the suprachiasmatic nucleus, activation of lipoxygenase in the rat aorta and by nitric and are present in lower concentrations in hippocampus, oxide and activation of guanylyl cyclase in the human brainstem, spinal cord and dorsal root ganglia [6, 14, 29, 31] .
uterine artery [48] [49] [50] . In the bovine intrapulmonary VPAC2 receptors are also present in the aortic endoartery, endothelial-dependent vasorelaxation in response to thelium, heart, pancreas, renal medulla, adrenal cortex, VIP involves activation of guanylyl cyclase and cycloskeletal muscle, and adipose tissue [14, [28] [29] [30] [31] . Invesoxygenase through two pathways, which are probably tigations are focused at the present time on developing mediated by nitric oxide and prostacyclin [49] . In this specific agonists and antagonists for the VIP receptor system, cyclic AMP and cyclic GMP may interact synersubtypes. Currently available are specific VPAC1 receptor gistically to initiate and sustain the vasodilatory response 16 15 16 agonists ([Arg ]chicken secretin and [Lys , Arg , to VIP [51] . The vasorelaxant effect of VIP is independent 27 Leu ]VIP (1-7)GRF (8-27)-NH ), VPAC2 receptor of the endothelium in the feline middle cerebral artery 2 agonists (Ro 25-1553 and Ro 25-1392), and a VPAC1 [33, 52] , canine carotid artery [53] , canine hepatic artery
Lys , [54] , porcine coronary artery [55] and the rat portal vein 16 Arg ]VIP(3-7)GRF(8-27)-NH ) [23] . [43] . Moreover, the vasorelaxant effect of VIP in some 2 VIP combines with its receptor and dose-dependently species may ultimately involve hyperpolarization of the activates adenylyl cyclase, as demonstrated in cerebral vascular smooth muscle membrane, which reduces calcium sarcoplasmic reticulum (Fig. 2) . As a consequence, the The precise contributions of cyclic AMP, cyclic GMP, intracellular calcium concentration increases, enhancing nitric oxide and other signaling agents to the vasodilation cardiac myocyte tension development and the rate and elicited by VIP in different vascular beds is not known. extent of contraction [64] . An increase in cAMP can also One possible mechanism for the interaction between these increase troponin I and phospholamban phosphorylation, mediators of vasodilation is present in gastrointestinal which decreases the affinity of troponin for calcium, smooth muscle, in which VIP elicits relaxation via activaenhances intracellular calcium sequestration, and subtion of both cyclic AMP and cyclic GMP-dependent sequently enhances the rate and extent of myocyte relaxapathways [59, 60] (Fig. 2) . The increase in cyclic AMP is tion [64] . In this manner, VIP can increase cardiac myocyte due to activation of VPAC receptors [61] , whereas the contraction and relaxation. These effects of VIP on cAMP increase in nitric oxide may be due to activation of and L-type calcium current are significantly decreased by natriuretic peptide clearance receptors (NPR-C) coupled to VIP antagonists, including VIP(7-28) / neurotensin or [Na membrane-bound endothelial nitric oxide synthase [62] .
acetyl-Tyr-D-Phe2]GRF [40, 65] . Whether a similar interaction exists in vascular smooth
In the sinoatrial node, a VIP-induced increase in cAMP muscle or in the heart is presently not known and is under can activate the hyperpolarization-activated pacemaker I f investigation.
current and accelerate the rate of diastolic depolarization After VIP binds to its receptor, the peptide is rapidly and increase the heart rate [66, 67] . The VIP effect on the I f internalized, probably by receptor mediated endocytosis current is reversed by the VIP antagonist [4Cl-D-6 1 7 [63] . This internalization decreases the cell surface rePhe ,Leu ]VIP [66, 67] . ceptor density. Most of the receptors are recycled back to Hypertension, obesity, diabetes, and hypothyroidism the cell surface, but some receptors are degraded in reduce the adenylyl cyclase response to VIP in cardiac lysosomes [63] . The complete cycle of internalization and myocytes [68] [69] [70] . In the spontaneously hypertensive rat, recovery of the receptor requires a half-time of 13 min the activation of adenylyl cyclase in response to VIP is [63] .
impaired by as much as 69% [68, 69] . In contrast, the In ventricular myocytes, a VIP-induced increase in activation of adenylyl cyclase in response to the stable cAMP can increase protein kinase A activity, which guanosine 59-triphosphate (GTP) analogue, Gpp(NH)p, or enhances calcium channel phosphorylation, the L-type sodium fluoride (NaF) is not altered. Moreover, the EC 50 M) in the frontal cortex and hypothalamus [76] .
VIP undergoes a circadian rhythm with peak concentrations occurring in the plasma at 1800 h in the elderly and at 2000 h in young individuals [71, 72] . During strenuous exercise, plasma VIP concentrations can increase by as much as 100% and persist for more than 20 min after the termination of exercise [72] . This VIP response to exercise is significantly decreased by a glucose infusion, which suggests that VIP has an energy mobilizing function during exercise [72] . In patients with gastrointestinal VIP tumors, which produce a watery-diarrhea syndrome, the The major sites of VIP metabolism are the lungs, the liver, and the kidneys. Metabolism of VIP does not occur myocardial contraction and heart rate. cAMP can also increase Ca
VIP physiological actions in the heart
influx and can activate protein kinase G (cG-kinase). In arteries, cA-21 kinase increases Ca extrusion and sequestration, which lowers intracel-
21
In the heart, VIP immunoreactive nerve fibers are present lular Ca concentration, decreases myosin-actin affinity and induces hyperpolarization, thereby producing vasodilation. In gastrointestinal in the epicardial coronary arteries and veins, the sinoatrial smooth muscle [62] and possibly in the heart, VIP also interacts with node, atrium, interatrial septum, atrioventricular node, natriuretic peptide clearance receptors (NPR-C receptors). These receptors intracardiac ganglia, and ventricles (right ventricle4left are coupled to inhibitory G proteins (Gi1-2), coupled to activation of ventricle) [80] . VIP fibers in the heart arise from postmembrane bound NO synthase (NOS). Gi proteins may inhibit adenylyl ganglionic parasympathetic (vagal) neurons and also intrincyclase. In the heart, vascular smooth muscle and endothelium, nitric oxide synthase (NOS) and calmodulin are tightly bound to each other in sic nerve fibers [80, 81] . the membrane or exist as separate entities. Nitric oxide (NO) activates soluble guanylyl cyclase (GC), leading to synthesis of cGMP and 2.1. Coronary artery effects of VIP activation of protein kinase G (cG-kinase). Protein kinase G induces 21 21 protein phosphorylation, reducing intracellular Ca concentration, Ca VIP is present in the proximal coronary arterial walls in sensitivity, and vascular smooth muscle tone. Cyclic GMP-dependent 212 protein kinase can also reduce myocardial contractility and heart rate.
concentrations of 1.2-2.2310 mol / g tissue (¯1.2-
29
Activation is indicated by a solid line and inhibition by a dashed line.
2.1310 M) and may contribute to the regulation of normal coronary vasomotor tone [79, 82] . Conversely, values for the effects of VIP on adenylyl cyclase activity decreases in the VIP concentration in the coronary arteries remain unaltered, indicating that the receptor affinity is not may contribute to coronary spasm [82] . The effects of VIP impaired. Instead, there appears to be a specific decrease in on the coronary arteries have been studied in isolated the density of the VIP receptors or the coupling of the vascular tissue, in intact hearts and animals, and in receptors to adenylyl cyclase in hypertensive rats [68, 69] .
patients. In each of these studies, VIP produces significant coronary dilation. The vasodilatory effects of VIP on 1.3. Plasma concentrations of VIP arteries are much greater than on veins because of the greater VIP receptor density in arterial vessels [83] . VIP that circulates in the plasma of normal individuals
In contracted isolated coronary vascular strips, VIP, in 29 originates from VIP-containing nerve fibers in the gastroinconcentrations of approximately 1-3310 M, decreases testinal tract and also reflects peptide overflow from vascular tension by as much as 94% of the control tension vascular nerves [71- concentrations of 3310 -3310 mol intraarterially, usually released during low frequency nerve stimulation. increases the epicardial coronary artery cross-sectional area VIP, released during cardiac vagal nerve stimulation, by 27%, decreases coronary vascular resistance by 46%, increases coronary artery blood flow by as much as 62% in and increases coronary artery blood flow by 200% [82, 88] .
dogs in which aortic pressure and heart rate are maintained This significant decrease in coronary vascular resistance at a constant level and the muscarinic and b-adrenergic and increase in coronary blood flow suggests that VIP can receptors are blocked with atropine and propranolol [92] . act on the coronary microcirculation. The coronary dilator Following the termination of vagal stimulation, coronary effect of VIP, at maximal doses, is significantly greater artery flow returns gradually toward the baseline over 30 than that of isoproterenol [89] . min due, most probably, to the slow lymphatic elimination In healthy dogs and in dogs with cobalt-induced carof endogenous VIP [78, 91, 92] . The increase in coronary in normal dogs, VIP increases the coronary blood flow by When the VIP antagonist, [4Cl-D-Phe ,Leu ]VIP, is di-77%, the cardiac index by 55%, but also increases myocarrectly injected into the coronary artery of these animals, dial oxygen consumption by 40% [84] . At the same time, the coronary artery blood flow does not increase during the percent oxygen extracted from the coronary blood by vagal stimulation [91] . This antagonist is sensitive and the myocardium decreases as the transcoronary sinus selective for VIP and does not inhibit the receptors for oxygen difference declines by 16% [84] . These results glucagon, peptide histidine isoleucine, bombesin, suggest that VIP can increase coronary blood flow in cholecystokinin, calcitonin gene-related peptide, or subexcess of an increase in myocardial oxygen requirements.
stance P [91] [92] [93] [94] . VIP administered to patients produces similar hemo-
The effect of endogenous VIP on coronary arterial dynamic effects on coronary blood flow. The effect of VIP pressure also has been studied in dogs in which the left on myocardial oxygen requirements is directly dependent coronary artery blood flow is maintained at a constant level on the dose of VIP and the method of administration.
and the muscarinic and b-adrenergic receptors are blocked
212
When VIP, in doses of 3-90310 mol / min, is infused with atropine and propranolol [92] . Vagal stimulation in directly into the left coronary artery of patients, the major these animals causes coronary dilation and significantly determinants of myocardial oxygen consumption (preload, decreases coronary artery pressure by 17%, even though afterload, contractility, and heart rate) do not change [88] .
the major determinants of myocardial oxygen consumption Moreover, the myocardial extraction of oxygen as meado not change. Moreover, the coronary artery pressure sured by the transcoronary sinus O content difference remains 16% below the control value for more than 10 min 2 decreases progressively in comparison with the baseline after the termination of vagal stimulation [92] . However, extraction [88] . When VIP is infused intravenously, in after the injection of a VIP antagonist directly into the 210 doses of 0.5-2.0310 mol / kg / h, the coronary vascular coronary artery, vagal stimulation does not decrease resistance decreases by 33% and the systemic and the coronary artery pressure [92] . These two investigations pulmonary vascular resistances decrease by 31 and 24%, suggest that VIP directly dilates coronary arteries by acting respectively. However, the myocardial oxygen consumpon specific VIP receptors in the coronary arteries rather tion also increases by 18-25% [90] . These results suggest than by acting on muscarinic or b-adrenergic receptors or that VIP causes significant direct coronary artery dilation indirectly producing vasodilation. when administered intracoronary or intravenously but that
The release of VIP in the heart and the VIP conintravenous VIP can also cause indirect coronary vasodilatcentration in the coronary sinus blood is also increased ion by increasing myocardial oxygen requirements. The during coronary artery occlusion and during reperfusion VIP-induced coronary vasodilation is not mediated by [95, 96] . In isolated perfused rat hearts in which coronary prostaglandins or other cyclooxygenase products, since the perfusion is interrupted for 30 min, the VIP concentration coronary sinus concentration of 6-keto-prostaglandin F1a in the coronary effluent increases by 250%, from 1 to 212 does not increase during the infusion of VIP and cyclo-3.5310 M, during the ensuing 60-min reperfusion oxygenase inhibition does not significantly decrease the period [95] . Moreover, coronary perfusion with VIP immecoronary vasodilation [90] .
diately prior to the induction of ischemia significantly Endogenous VIP is released in the coronary vessels and decreases the myocardial release of creatinine kinase and heart during parasympathetic (vagal) nerve stimulation and the formation of hydroxyl radicals, and inhibits calcium also produces significant coronary artery dilation overload in cardiac myocytes [95] [96] [97] . As a consequence, [78, 91, 92] . The magnitude of the coronary dilation is the postischemic reduction in coronary artery flow is directly dependent on the frequency of vagal nerve stimusignificantly decreased. These studies suggest that VIP lation [91, 92] . In this regard, VIP is most readily released promotes local blood flow in the heart during acute during high frequency vagal nerve stimulation in contrast myocardial ischemia and may also have a free-radical to the classical neurotransmitter acetylcholine, which is scavenging effect thereby decreasing possible cardiac myocyte calcium overload [95] [96] [97] [98] . Inhibition of nitric increase is totally independent of b-adrenergic receptor oxide appears to decrease the cardioprotective properties of stimulation [89, 108, 109] . However, the inotropic response VIP [97] . This suggests that VIP may act in the heart, in to VIP, but not the coronary vasodilator response, may part, through nitric oxide. diminish with increasing VIP dose and / or with time and is The VIP plasma concentration also increases in patients probably due to VIP receptor desensitization in the with acute coronary occlusion. In patients with acute myocardium [113] . myocardial infarction, the VIP concentration in the plasma Endogenously released VIP increases atrial and premay increase by 33-62% within 6 h of the onset of dominantly right ventricular contractility. Stimulation of symptoms but then abruptly decreases below the normal the parasympathetic (vagal) nerves, during muscarinic and concentration after 24 h [99, 100] . VIP reaches its lowest b-adrenergic receptor blockade in dogs in which right plasma concentration 48 h after the onset of symptoms of atrial contractile force is continuously monitored, increases myocardial infarction and then gradually returns to the the atrial contractile force by 32% [114] . However atrial normal concentration by day 14 [99, 100] . With acute contractile force does not increase after the VIP antagonist, 6 1 7 coronary occlusion, VIP is released from neurons in the [4Cl-D-Phe ,Leu ]VIP, is injected into the right atrial coronary vessels and myocardium, and may also be muscle by way of the right coronary artery [114] . Vagal released from the splanchnic viscera, and can act as a nerve stimulation, in a frequency dependent manner, also vasodilator to reduce myocardial ischemia. In this manner, significantly increases right ventricular contraction and VIP can counteract the vasoconstrictive effects of the relaxation by 28 and 33%, respectively, but only slightly, sympathetic and renin-angiotensin system [95, 96, 98] . The but not significantly, increases left ventricular contraction abrupt decrease in the VIP plasma concentration 24-48 h and relaxation in dogs in which the muscarinic and bafter the onset of infarction is due to either depletion of adrenergic receptors are blocked and the heart rate con-VIP from nerve endings or to the impairment in the trolled [91, 92, 115] . The right ventricular inotropic and neurogenic synthesis and release of VIP in the heart lusitropic response is significantly inhibited by the inbecause of depletion of high energy phosphates [100] . In jection of a VIP antagonist into the right coronary artery patients who die from acute myocardial infarction, the VIP [91, 115] . These positive right, but not left, ventricular plasma concentrations do not normalize but rather remain inotropic and lusitropic responses are best explained by the significantly lower than the VIP concentrations of patients fact that distinct VIP immunoreactive fibers are present in who survive [100] .
the atria and right ventricle, but the distribution of VIP The vasodilator effect of VIP is not limited to the fibers is not abundant in the left ventricle [80, 115, 116] . coronary arteries. Endogenous or exogenous VIP also
In animal models of heart failure and in patients with produces significant arterial dilation in other body organs.
cardiomyopathy, the concentration of VIP can decrease in For example, exogenous VIP significantly increases cerethe myocardium by more than 50% [117] . Moreover, the bral arterial blood flow as well as blood flow to the eyes, VIP receptor density decreases by as much as 62% and is parotid, thyroid and pancreatic glands [101] [102] [103] . In associated with a similar (62%) decrease in the myocardial addition, endogenous VIP significantly increases blood contractile response [24, 117] . However, the affinity of the flow to the salivary glands and the uterus [104, 105] .
remaining receptors for VIP may increase [24] . This increased VIP receptor affinity contrasts with b-adrenergic 2.2. Cardiac inotropic effects of VIP receptors in heart failure, where the density of b1-adrenergic receptors is decreased and b2-adrenergic receptors VIP has a primary positive inotropic effect on cardiac are mildly uncoupled [24] . In this regard, changes in muscle that is enhanced by its ability to reduce systemic cardiovascular VIP receptors or VIP signaling pathways arterial mean pressure by 10-15%, thereby facilitating may be important in the pathogenesis of heart failure and ventricular-vascular coupling [84, 106, 107] . When added hypertension. Interestingly, in patients with congestive to isolated atrial or ventricular muscle in tissue baths, VIP, heart failure or circulatory shock the plasma concentration 28 25 in doses of 10 -10 mol, augments developed isometric of VIP can increase by 400% or more [118, 119] . However, force by more than 40% and is equal to or greater than this increase in the plasma VIP concentration may be due isoproterenol in enhancing ventricular muscle contractile to gastrointestinal ischemia or significant decreases in the force [108, 109] . Exogenous VIP is similar to isoproterenol hepatic and / or renal clearance of VIP because not all and forskolin in increasing the rate of change of ventricular patients with congestive heart failure or circulatory shock pressure per unit time (dP/dt) in research animals in which demonstrate an increase in the plasma VIP concentration the cardiac output, arterial pressure, and heart rate are held [118, 120] . constant [89, 110, 111] . In patients, VIP, given intravenously 210 in doses of 4310 mol / kg / h, increases the left ventricu-2.3. VIP effects on heart rate lar shortening fraction by 38% while intracoronary VIP, in 211 doses of 9310 mol / min, produces a small but signifiThe discovery that VIP-immunoreactive fibers occur in cant increase in left ventricular dP/dt [88, 112] . This high density in and around the sinus node and the atrioventricular node of all mammals strongly suggests that stimulation or to exogenous norepinephrine in which the VIP can modulate the electrical responses of the heart and time to peak heart rate and the duration of the tachycardia can affect the heart rate [80, 121] . The co-release of VIP are much shorter. In addition, the time to peak heart rate with acetylcholine in the sinoatrial and atrioventricular and the maximal heart rate response resemble the heart rate nodes may prevent potentially dangerous neurally meresponses in subjects with 'postvagal tachycardia' and the diated bradyarrhythmias [66, 67] . In this regard, VIP may heart rate responses of research animals with 'excess oppose elevated acetylcholine concentrations in the tachycardia' (i.e. the heart rate response in animals after sinoatrial node that inhibit the pacemaker I current and muscarinic blockade minus the heart rate response that f activate muscarinic potassium conductance that might occurs after vagotomy) [114, 115, 123, 130] . The transmitter otherwise lead to arrest of spontaneous electrical activity responsible for 'postvagal tachycardia' and 'excess tachy- [66] .
cardia' is most likely VIP rather than the classical neuroWhen VIP is injected directly into the sinoatrial artery of transmitters norepinephrine or acetylcholine. dogs, in which the muscarinic and b-adrenergic receptors are blocked, the heart rate increases over 40 s by as much as 37% [122] [123] [124] . The heart rate then returns to the 3. Conclusions baseline over 5-10 min [122] . The magnitude of the VIP-induced increase in heart rate appears to be inversely
The presence of VIP in the vagal centers of the medulla related to the extent of vagal cardiac accelerator activation oblongata and the significant concentration of VIP in the prior to the injection of VIP [125] . Accelerations in heart branches of the vagal nerves and in the heart and coronary rate, similar to those observed in research animals, occur arteries suggest that this peptidergic neurotransmitter plays when VIP is given intravenously to patients [112] . In an important role in the regulation of coronary blood flow, addition, VIP, in a dose dependent manner, can shorten the cardiac contraction and relaxation, and heart rate. Moreatrioventricular conduction time by as much as 37%, and over, the altered affinity, density, and physiological recan decrease the atrial and ventricular refractory periods by sponsiveness of VIP receptors in heart failure and hy-25 and 10%, respectively, as demonstrated in a dog model pertension suggests that these alterations may have an [126] but not in a rabbit model [127] . On a molar basis, important pathophysiological function. Additional inves-VIP can have a more potent effect on heart rate than does tigations are necessary to define the precise physiologic norepinephrine [122] . Consequently, VIP appears to be one role of VIP in the regulation of cardiovascular function. of the most potent positive chronotropic and dromotropic neuropeptides [122] . Moreover, the responsiveness of the cardiac automatic cells to exogenous VIP does not appear Acknowledgements to diminish appreciably over time.
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